Abbott ulcerative colitis drug Phase III trial meets primary endpoint
The study has evaluated 494 adult patients with UC who had not responded well to conventional therapy, such as corticosteroids and/or immunosuppressants. In the trial, 16.5% of the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.